Symbolbild · KI-generiert
Larimar Therapeutics, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Larimar Therapeutics is a clinical-stage biotechnology company focused on developing therapies for rare diseases, in particular Friedreich's ataxia. The drug candidate Nomlabofusp (CTI-1601) is a cell-penetrating fusion protein designed to replace mitochondrial frataxin. The company is in the clinical trial stage.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Larimar Therapeutics, Inc. | LRMR | NASDAQ | 397 Mio. USD |
| Autolus Therapeutics plc | AUTL | NASDAQ | 397 Mio. USD |
| Assembly Biosciences, Inc. | ASMB | NASDAQ | 399 Mio. USD |
| Sutro Biopharma, Inc. | STRO | NASDAQ | 401 Mio. USD |
| BioAge Labs, Inc. | BIOA | NASDAQ | 402 Mio. USD |
| Benitec Biopharma Inc. | BNTC | NASDAQ | 402 Mio. USD |
| Puma Biotechnology Inc | PBYI | NASDAQ | 404 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.